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Objectives: In order to investigate real-world values data; blood pressure, LDL-c, 
and HbA1c, in Japan from various perspectives and to assess the degree to which 
health condition in Japan is reflected in database, we conducted a comparative 
assessment using three databases: Minacare database, a large database containing 
health care checkup results from employment-based health insurance recently 
developed, and the publicly available two nation-wide databases. MethOds: A 
retrospective, cross sectional study using the Japanese health care checkup data-
base developed by MinaCare Co. Ltd. was designed to investigate the distribution 
of the real-world values of BP, LDL-c, and HbA1c in Japan. The data were compared 
to those in Specific Health Checkups and Specific Health Guidance (MHLW-SH) and 
National Health and Nutrition Survey (MHLW-H&N). Results: There were 232,515 
subjects with health care checkup results in 2011 MinaCare database. The propor-
tion of subjects with SBP≥ 140 mmHg, LDL-c≥ 140 mg/dL, and HbA1c≥ 6.1% generally 
increase with age; in the 55-60 year age range, the proportions were 19.0% (males) 
and 12.2% (females) for SBP, 27.2% and 42.7% for LDL-c, and 13.5% and 5.4% for 
HbA1c, respectively. The MinaCare database was mostly comparable to MHLW-SH 
and MHLW-H&N databases. However, some notable differences were seen for MHLW-
H&N compared to MinaCare and MHLW-SH in the values of BP and lipid param-
eters. cOnclusiOns: Analysis of MinaCare database indicated that substantial 
proportions of subjects have BP, LDL and HbA1c levels that are not well controlled 
in accordance with the Japanese guidelines. The results were generally consistent to 
the national databases. In light of the characteristics of MinaCare database such as 
the low selection bias, large sample size, wide age distribution, and high flexibility 
in the analysis of subject-level data, the database is highly valuable in studying the 
health status of the population insured by the employment-based health insurance.
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ComParison of atrial fibrillation DeCision suPPort tools anD 
GuiDelines useD to GuiDe antiCoaGulation theraPy for Patients 
With nonValVular atrial fibrillation
Shewale A.R., Nelsen D.A., Johnson J.T., Li C., Martin B.
University of Arkansas for Medical Sciences, Little Rock, AR, USA
Objectives: The American College of Chest Physicians, the European Society 
of Cardiology guidelines, and published decision support tools by LaHaye and 
Casciano offer recommendations to guide oral anticoagulant (OAC) treatment in 
patients with atrial fibrillation (AF). The aim of our study is to compare the predic-
tive validity of these aids by contrasting the net clinical benefit when OAC use is 
concordant/discordant with each of the aids. MethOds: A cohort study using the 
2006-2013 Lifelink claims data was used to compare the net clinical benefit (NCB) 
of AF patients. NCB is the difference in event rates of composite events (thrombo-
embolic stroke and major bleed events per 10,000 person years) between patients 
who are concordant and those who are discordant with the guideline/tool recom-
mendations. Cox proportional hazard models were used to assess the relative risk 
of composite thromboembolic and bleed events adjusted for potential confound-
ers. Results: A total of 11,315 AF patients contributing 27,801 person years met 
the study inclusion criteria. The NCB of patients concordant with recommendations 
of the LaHaye tool (34.81[C.I= 33.4-36.23]) was highest followed by American guide-
lines (22.75[C.I= 21.40-24.17]), Casciano tool (16.99[C.I= 15.57-18.40]) and European 
guidelines (3.94[C.I= 2.52-5.35]). By restricting the definition of composite events to 
ischemic stroke and intracranial hemorrhage; the NCB of patients concordant with 
American guidelines (24.20[C.I= 22.88-25.52]) was highest followed by Casciano tool 
(17.07[C.I= 15.75-18.38]), LaHaye tool (14.30[C.I= 12.99-15.62]) and European guide-
lines (11.25[C.I= 9.93-12.57]). There was no significant decrease in the risk of com-
posite events associated with concordant OAC use/non-use for any of the decision 
aids after multivariate adjustment. cOnclusiOns: These results suggest that OAC 
use/non-use consistent with any of the tools led to net clinical benefits but the rank 
order depended on the composite outcomes selected. However, the benefit vanished 
after multivariate adjustment. Larger studies are warranted before any one OAC 
decision aid can be recommended to routinely guide OAC treatment decisions.
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Objectives: Published atrial fibrillation (AF) guidelines and decision tools offer 
oral anticoagulant (OAC) recommendations however they consider stroke and 
bleed risk differently. The aims of our study are to (i)empirically compare the treat-
ment recommendations by the American College of Chest Physicians guidelines, 
the European Society of Cardiology guidelines, and two published decision tools 
published by Casciano and LaHaye and (ii) to compare the concordance of OAC 
use with their recommendations. MethOds: A cross sectional study using the 
2006-2013 Lifelink claims data was used to contrast the treatment recommenda-
tions of these AF-OAC decision aids. CHADS2VASc and HAS-BLED algorithms were 
used to stratify 11,315 AF subjects into 9 stroke and bleed risk groups to study the 
variation in treatment recommendations. The concordance of actual OAC use with 
each of the decision aid’s treatment recommendations was compared. Results: 
The European guidelines recommended OAC most often (84.96%) and a conserva-
tive LaHaye tool recommended warfarin OAC the least often (13.41%). None of the 
decision aids recommended OAC for subjects with low stroke risk (CHADS2VASc= 0). 
However, OAC treatment recommendations varied considerably when stroke risk 
was moderate or high (CHADS2VASc> 0). For example, the LaHaye tool never recom-
mended warfarin OAC for persons with CHADS2VASc= 1 irrespective of bleed risk, 
however, the European guidelines preferred OAC for persons with CHADS2VASc= 1 
and a HAS-BLED< 3. Actual OAC use was most consistent with the Casciano tool 
(49.43%) and was least consistent with the LaHaye tool (44.52%). cOnclusiOns: 
OAC prescribing could be improved as actual OAC use/non-use was often discordant 
with all the recommendations. There is considerable variability in OAC treatment 
recommendations by the AF guidelines and decision tools when ischemic stroke risk 
is moderate or high. Empirical evidence is needed to compare the outcomes of OAC 
treatment recommendations by each of these decision aids before implementing 
one of these to inform clinical decisions.
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use of ProDuCt life CyCle (PlC) to unDerstanD aDVertisinG 
strateGies useD by PharmaCeutiCal ComPanies: a Pilot stuDy
Kumari P., Muzumdar J.M., Nania A., Nayak R., Shanbhag P.
St. Johns University, Fresh Meadows, NY, USA
Objectives: Pharmaceutical companies utilize various promotional strategies to 
advertise a drug during its patent life. Study purpose was to understand these strate-
gies by exploring the content of drug advertising using the framework of Product 
Life Cycle (PLC). During different stages of PLC, this study assessed drug ads for 
the following: (1) type of characters appearing in the ad, (2) source of information 
(SOI) for the drug, and (3) ad appeals (rational vs. emotional). MethOds: Unique 
ads of Pfizer, Inc. drug Lipitor (Atorvastatin), aired during CNN evening news (from 
Jan 1st ’96 – Nov 30th ’11 [patent life of Lipitor]), were evaluated. The Vanderbilt TV 
News Archive provided the advertising content. PLC phases were defined as fol-
lows: introduction and growth (Phase-I: 1999-2002); maturity (Phase-II: 2003-2006); 
and decline (Phase-III: 2007-2011). Code sheet was developed using prior literature 
and pilot-tested for the final study. Four coders were trained in coding procedures. 
Reliability was measured with Cohen’s kappa. Data were analyzed using descrip-
tive statistics and cross-tabulations. Results: Twenty-one (phase-I: 2; phase-II: 7; 
phase-III: 12) unique product-specific ads were analyzed. Researchers of the adver-
tised drug appeared more in phase-II [3 (43%) of 7 vs. 3 (25%) of 12 in phase-III)]. 
Person with medical condition appeared more in phase-III [9 (75%) of 12 vs 4 (57%) of 
7 in phase-II)]. In all three phases an anonymous voice provided drug information. 
Researchers were a SOI in phase-II [3 (43%) of 7 ads] and a person with medical con-
dition was a SOI in phase-III [7 (58%) of 12]. The appeal of phase-II ads was rational 
compared to ads in phase-III [4 (57%) of 7 vs. 5 (43%) of 12 ads]. cOnclusiOns: 
Distinctive ad strategies were observed throughout the PLC of Lipitor. These dif-
ferentiated strategies coincided with shifts in PLC phases, which indicate a change 
in ads based on the phase of PLC.
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eValuation of meDiCal Quality baseD on reaDmissions Within 30 
Days amonG benefiCiaries in Central illinois
Asche C.1, Ren J.1, Hippler S.E.2
1University of Illinois, Peoria, IL, USA, 2OSF Medical Group, Peoria, IL, USA
Objectives: To evaluate the medical quality of a Central Illinois health care 
system by developing a predictive model to identify those patients who might 
be more likely to be readmitted with 30 days of discharge based upon their fac-
tors, determinants and demographic/clinical characteristics. MethOds: This is 
a retrospective study integrating the information compiled in a Central Illinois 
hospital administrative database from 2010 to 2013 of patients admitted with 
acute myocardial infarction (AMI), Heart Failure (HF) or Pneumonia, capturing 
data including readmissions within 30 days, diagnosis, treatment, gender, age, 
education, race, medical insurance, health care provider, specific comorbidities 
etc… A multivariable generalized linear model and Bayesian analysis were used to 
predict adjusted hospital readmission rates including all-cause, AMI, HF and pneu-
monia. Results: The average adult readmission rates were 15.2% (1554/10244) 
for all-cause, 8.9% (272/3058) for AMI, 15.6% (583/3740) for pneumonia and 20.3% 
(699/3446) for HF. Among adults higher readmission rates were significantly more 
likely to occur among Black Americans (21.2% of all readmissions), those who have 
separated, divorced or widowed (17% of all readmissions), elderly with AMI, those 
individuals living in metropolitan areas (16.6% of all readmissions), underweight 
individuals (26% of all readmissions), and those individuals with longer length 
of stay and comorbidities. The HF and AMI specific admission data were utilized 
to develop and test the predictive model. The sensitivity and specificity were 
56.1% and 57.6% for HF and 67.9% and 66.6% for AMI, respectively. cOnclusiOns: 
Predictive modeling can serve to identify patients who could be more likely to be 
readmitted. More information is required to improve the accuracy of the model. 
The model could be operationalized in a hospital setting to identify high-risk 
individuals who may benefit from interventions upon discharge.
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hosPital Quality sCores Versus meDiCare CharGes anD 
reimbursement – What is the assoCiation?
Miyasato G.S, Wang Z., Meckley L.M.
Trinity Partners, LLC, Waltham, MA, USA
Objectives: In 2011, the US Centers for Medicare and Medicaid Services (CMS) 
established the Hospital Value-Based Purchasing (HVBP) program in which hospitals 
were assigned quality scores related to their treatment of inpatients. The primary 
objective of this study was to measure, among acute myocardial infarction (AMI) 
and heart failure (HF) inpatients, the association between hospital quality of care 
scores and the difference between hospital charges and reimbursement amounts 
(the Delta). This research has potential implications related to inpatient procedure 
quality measures and hospital charging behavior. MethOds: The Delta between 
hospital charges and reimbursement was calculated for patients with an AMI or HF 
from 2011 Medicare inpatient claims. Quality was assessed with CMS’s 2011 Hospital 
Compare AMI and HF quality component scores. To measure the adjusted associa-
tion between the Delta and quality scores, generalized linear mixed models were fit 
separately for AMI patients and HF patients. The models controlled for both patient 
and hospital characteristics. Results: The AMI model was fit using 110,076 claims 
across 1,383 hospitals. After controlling for patient and hospital factors, each 1-point 
increase in AMI quality score yielded a 0.5% increase in Delta (p-value = 0.01). The 
HF model was fit using 468,974 claims across 2,813 hospitals. The adjusted HF model 
revealed that a point increase in HF quality score yielded a 1.0% increase in Delta 
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patients with type 2 diabetes mellitus (T2DM). This study explored the association 
of race/ethnicity and gender with complications severity, HRU, and costs among 
Medicare Advantage patients. MethOds: A retrospective cohort study was per-
formed using medical and pharmacy claims of 333,576 Medicare members enrolled 
from 1/1/2010 to 12/31/2011, aged 18 to 89, and with ≥ 1 medical claim with primary 
diagnosis or ≥ 2 medical claims with secondary diagnosis of T2DM (ICD-9-CM 250.
x0 or 250.x2). Complications severity was assessed with the Diabetes Complications 
Severity Index, with scores of 0 (no complications) through 5+ (five or more). HRU 
was reported by mean (standard deviation [SD]) number of outpatient, inpatient, 
and emergency room [ER] visits. Costs were reported as means (SD) of medical, 
pharmacy and total health care costs evaluated. Associations of race/ethnicity and 
gender with the three outcomes were evaluated using generalized linear regression 
models. Results: The sample was older (70.81 ±8.8 years) and 80% White. Being 
Hispanic, Black, or male was associated with a higher prevalence of more severe 
T2DM complications; this disparity was more pronounced among females, with 
the odds of having more severe complications being higher for Hispanic and Black 
females compared to White females (Hispanic v. White odds ratio [OR], 1.40; 95% 
confidence interval [CI], 1.32-1.48), and (Black v. White OR, 1.22; 95% CI, 1.19-1.25). 
Regardless of gender, Blacks had more ER visits than Whites. Whites, particularly 
females, incurred the highest total annual health care costs, (White female costs: 
$13,086; 95% CI, $12,935-$13,240) vs. (Hispanic female costs: $10,732; 95% CI, $10,406-
$11,067). cOnclusiOns: Racial/ethnic and gender differences exist in certain T2DM 
clinical and economic outcomes. Following these specific patients’ progress more 
closely may prevent or delay complications and decrease long term costs
Phs3
maternal morbiDity anD mortality in eClamPtiC Patients: a CliniCal 
stuDy in bahaWalPur, southern Punjab With soCio-eConomiC 
asPeCts
Ashraf MN1, Batool F1, AlSharari S2
1The Islamia University of Bahawalpur, Bahawalpur, Pakistan, 2King Saud University, Riyadh, 
Saudi Arabia
Objectives: Eclampsia remains a major cause of maternal morbidity and mortal-
ity worldwide. In underdeveloped countries, the mortality rate is even higher due 
to the poor access to the health care, socio-economical problems and the cost of 
the treatment involved therein. To find out the trends and maternal outcomes in 
eclampsia in the region, a study was carried in a tertiary care unit i.e. Department 
of Gynaecology/Obstetrics, Bahawal Victoria Hospital (BVH), Bahawalpur, Pakistan, 
with the collaboration of Department of Pharmacology, King Saud University, Saudi 
Arabia. MethOds: A total no. of 67 (n = 67) patients presented with eclampsia 
were assessed for maternal morbidity and mortality outcomes during the period 
of 6 months. A prospective study using a cross- sectional descriptive design was 
used. The patients were evaluated for various parameters that included biologi-
cal aging, type of complications, literacy level, socio-economical status, and par-
ity. Results: The calculated mean age of the patients was 25.69 ± 8.42 years. The 
incidence was found to be higher in the extremes of the reproductive life (bimodal 
variation), and during ante partum stage (55.2%) followed by postpartum (31.3%) 
and intrapartum period (13.4%). Among the patients examined, 44.8% were found 
with no formal education, 25.4% having primary education only, and 74.6% patients 
belonging to the lower socio-economic class. The incidence of eclampsia was higher 
in nulliparous women (58.2%) as compared to multiparous (31.3%) and grand mul-
tiparous women (10.4%). The overall complication to non-complication ratio was 
found to be 38.8% to 61.2%, with morbidity and mortality rate of 38.8 % and 13.4%, 
respectively. cOnclusiOns: Keeping these finding in views, we may conclude that 
poor education, lack of effective health policies, and socioeconomic problems may 
contribute significantly to the morbidity and mortality associated with eclampsia 
in under developed regions.
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imPaCt of CarDioVasCular ComorbiDities on Patients With tyPe 2 
Diabetes mellitus: a systematiC reVieW
Vaidya V1, Gangan N2, Sheehan J3
1The University of Toledo, College of Pharmacy and Pharmaceutical Sciences, Toledo, OH, USA, 
2The University of Toledo, Toledo, OH, USA, 3Bristol-Myers Squibb, NJ, USA
Objectives: To conduct a thorough search of medical literature investigating 
the prevalence of cardiovascular comorbidities and its impact on health care 
costs, quality of life, and mortality among patients with type 2 diabetes mellitus 
(T2DM). MethOds: Keywords and Medical Subject Headings were used to perform 
a search using MEDLINE, Cochrane, CINHAL Plus, and PsychINFO. Eligible studies 
were: published in English before June 2013, included cardiovascular or other 
comorbidities of T2DM, outcome researched was prevalence, economic burden, 
age of onset, quality of life or mortality of cardiovascular or other comorbidi-
ties, and the sample size was larger than 50. Results: Seventy-six studies and 
reports were used in this systematic review. Cardiovascular disease (CVD), includ-
ing hypertension, was the most prevalent complication of T2DM. Total health care 
costs of diabetic patients with CVD ranged from $10,450 to $14,414 per-person 
per-year in the United States. Quality of Life was found to be significantly lower 
in diabetes patients with cardiovascular complications, while mortality was found 
to be much higher than either illness alone. cOnclusiOns: Prevalence of CVD 
is very high in T2DM patients with hypertension being the most prevalent. The 
additional cost burden due to CVD is also higher than any other comorbidity 
except End Stage Renal Disease (ESRD). Considering the much higher prevalence 
of CVD, compared with ESRD, increased cost due to CVD is likely to be higher than 
any other comorbidity at a population level. The quality of life was much lower in 
patients with CVD and diabetes, but not as low as in patients with comorbid pain-
ful neuropathy. Increased mortality was caused by the combination of diabetes and 
CVD. Cardiovascular complications in diabetes patients have a significant impact 
on the economic burden, quality of life, and the mortality rates. This research was 
funded by Bristol Myers Squibb.
(p-value < 0.0001). cOnclusiOns: After adjusting for patient and hospital factors, 
hospital quality scores (both AMI and HF) were not strongly associated with the large 
amounts some hospitals charge beyond the standard reimbursement amount. The 
lack of strong associations suggests that either: (1) quality scores were not indica-
tors of hospital resource utilization, or (2) hospital charges were not driven by the 
expenses incurred as a result of providing high quality services, furthering the 
argument for increased cost transparency from health care providers.
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Patients at a national institute of Care in Peru
Sanabria C.1, Cabrejos J.1, Guevara C.2, Olortegui A.2, Garrido Lecca S.3
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Objectives: To characterize treatment patterns and health care resource utilization 
among adults diagnosed with non-valvular atrial fibrillation (NVAF) at the Social 
Security system (EsSalud) in Peru. MethOds: Observational retrospective study 
based on medical chart review from the National Cardiovascular Institute (INCOR). 
The study included patients over 18 years of age, with a confirmed diagnosis of 
NVAF based on physician diagnosis and ICD-10 code, treated at INCOR NVAF in 
2011, allowing for a minimum potential follow-up of one year. Clinical study enroll-
ment or AF patients with valvular origin were excluded. For each eligible patient, 
information on patient and disease characteristics, treatments received, clinical 
outcomes, and AF-related health care resource utilization was captured. Patients 
were randomly selected from an electronic database until the predetermined sam-
ple size of 83 eligible patients was met. Results: The study population median 
age was 68.8 years, 66.3% were male. CHADS2 distribution was: 0-7.2%, 1–18.1%, 
2-18.1%, 3–32.5%, 4–18.1%, 5–6 % and 6-0%. 89.2% of patients with NVAF received 
at least one prescription during follow-up; distribution according to drug classes: 
77.0% heart rate control, 75.7% antiplatelets, 60.8% antihypertensives, 50.3% vitamin 
K antagonists and 44.6% anti-arrhythmic. A median of 30.2 diagnostic tests includ-
ing electrocardiograms and INR tests were performed per patient (range: 1 - 144). 
Twenty-three percent of patients had at least one procedure with implantation of 
a pacemaker being the most frequent procedure, followed by AV node ablation. 
30% of patients were hospitalized at least once during the study follow up period. 
Median hospital stay was 12.6 days (range:1-115). cOnclusiOns: NVAF manage-
ment is heterogeneous at INCOR, particularly for rhythm control, anticoagulation 
monitoring, and the utilization of anticoagulant therapy.
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ComorbiDities anD health resourCe use of ChroniC PlaQue Psoriasis 
Patients in CanaDa: a matCheD-Cohort stuDy
Gregory V1, Luciani L2, Barbeau M3, Petrella RJ4
1Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada, 2Université de Montréal, Montreal, 
QC, Canada, 3Novartis Pharmaceuticals Canada Inc., Montreal, QC, Canada, 4Lawson Health 
Research Institute, London, ON, Canada
Objectives: Compare the comorbidities and health care resource utilization of 
chronic plaque psoriasis compared to a matched control cohort in a large, Canadian, 
real-world dataset. MethOds: This was an observational, retrospective study of 
patients ≥ 18 years who, between 2008 and 2012 received a diagnosis of psoriasis 
and at least 1 treatment. Data were retrieved from the Southwestern Ontario (SWO) 
database, which is a representative primary care database of over 325,000 unique 
patient records in Ontario, Canada. Comorbidities and health resource utilization 
were recorded in the patient chart as per their health care provider. A matched 
control cohort was constructed based on age, gender and ethnicity. Differences 
between psoriasis and control groups were compared using paired and independent 
samples t-tests. Results: A total of 7,776 patients in the SWO database (n= 325,618) 
had a diagnosis of psoriasis and received at least 1 treatment between January 1, 
2008 and December 31, 2012. Of these, 85% had chronic plaque psoriasis. Over half 
of patients with chronic plaque psoriasis were diagnosed with hypertension (61%, 
similar in the control group), 11% had diabetes (vs 7% in control group), 4% had 
depression and/or anxiety disorders (vs 1%), 6% had insomnia (vs 1%). Thirty-two 
percent (32%) were overweight and 24% were obese (vs 27% and 19%, respectively). 
Patients with moderate to severe plaque psoriasis (28%) were more likely to visit 
their family physician than the control group (9 vs 3 visits per year, respectively). 
These patients missed more days of work than the control (11 vs 4, respectively) and 
recorded more work absences (2 vs 0.03 absence notes per year). cOnclusiOns: 
Chronic plaque psoriasis is a significant health condition and is associated with 
higher rates of comorbidity and use of health services in Canada, especially in 
patients with a moderate-severe condition.
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raCial/ ethniC anD GenDer DifferenCes in seVerity of Diabetes-
relateD ComPliCations, health Care resourCe use, anD Costs amonG 
meDiCare aDVantaGe reCiPients
Hazel-Fernandez L1, Li Y2, Nero D3, Moretz C2, Slabaugh SL2, Meah Y4, Baltz J4,  
Costantino ME2, Patel N2, Bouchard JR5
1Comprehensive Health Insights, Humana, Miramar, FL, USA, 2Comprehensive Health Insights, 
Inc., Louisville, KY, USA, 3Magellan Health Services, Glenn Allen, VA, USA, 4Humana Inc., 
Louisville, KY, USA, 5Novo Nordisk Inc., Plainsboro, NJ, USA
Objectives: Few studies have assessed racial/ethnic and gender differences in 
diabetes-related complications, health care resource utilization (HRU) and costs in 
